https://doi.org/10.55788/113c5394
In the real-world analysis presented by Prof. Adam S. Faye (NYU Langone Health, NY, USA), 2.3 million individuals aged 60 to 90 years were included and followed from 2000 to 2018 [1]. Prof. Faye and his colleagues used data from a nationwide registry in Denmark to assess the impact of cumulative antibiotic use, the timing of antibiotic use, and the association between specific antibiotic classes and the development of older-onset IBD.
From 2000 to 2018, 10,773 new cases of ulcerative colitis and 3,825 new cases of Crohn's disease were identified with diagnostic ICD-10 codes. Any antibiotic use was associated with a 64% higher risk of developing IBD (incidence rate ratio [IRR] 1.64). All antibiotic classes elevated the risk for IBD development, including those not used to treat a gastrointestinal infection. However, the risk differed between classes and was highest when fluoroquinolones (IRR 2.27), nitroimidazoles (IRR 2.21), and macrolides (IRR 1.74) were used. Moreover, there was a clear dose-response observed: 1 course of antibiotics was associated with an IRR of 1.27, 2 courses with an IRR of 1.54, going up to ≥5 courses with a staggering IRR of 2.35. Effect estimates were slightly higher for Crohn’s disease versus ulcerative colitis. The risk of developing late-onset IBD was highest in the first 1–2 years after antibiotic use but remained elevated for 5 years.
"Inflammatory bowel disease often can be overlooked in older adults because there's a lot of different diagnoses you're thinking of," said Prof. Faye. "It should be considered, especially if you have a patient reporting that they had multiple courses of antibiotics within the past few years." Prof. Faye pointed out that, while antibiotic stewardship is essential, "avoiding antibiotics at all costs is not the right answer either. If patients are coming in with clear infections and they need antibiotics, they should not be withheld because of these findings," he concluded.
- Faye AS, et al. Antibiotics as a risk factor for older-onset IBD: population-based cohort study. Lecture 400, Digestive Disease Week 2022, 21–24 May, San Diego, CA, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Too much hygiene: CD in later life? Next Article
Amylyx’s ALS drug would not be cost effective if priced around $170,000- ICER »
« Too much hygiene: CD in later life? Next Article
Amylyx’s ALS drug would not be cost effective if priced around $170,000- ICER »
Table of Contents: DDW 2022
Featured articles
Too much hygiene: CD in later life?
IBD
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
IL-23 inhibition beneficial in maintenance treatment of UC
Positive outcomes for etrasimod in UC
Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation
Upper GI
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cannabis users need more sedation medication for gastroscopy
Preterm delivery and NICU admission are associated with the development of eosinophilic oesophagitis
Dupilumab promising as treatment for eosinophilic oesophagitis
Other Highlighted Research
AI-assisted colonoscopy improves adenoma detection
Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections
Oral microbes effective for prevention of recurrent Clostridium difficile infections
Octreotide therapy beats standard of care in GIADs
Improvement in hepatic steatosis but worse lipid profile after alcohol cessation
Normal BMI in NAFLD patients is associated with a higher risk of cardiovascular disease
COVID-19 increases the mortality rates of patients with ALD
Related Articles
October 30, 2022
Inhaled agent under investigation for COVID-19
October 29, 2020
COVID-19 vaccines: An ongoing race
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com